Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 product, SHR1905. This product is a hymic stromal lymphopoietin (TSLP)-targeted monoclonal antibody (mAb) intended for the treatment of chronic obstructive pulmonary disease (COPD).
As a novel therapeutic with no similar products approved globally for COPD, SHR1905 garnered significant attention with an out-licensing deal exceeding USD 1 billion with US-based biotech company One Bio Inc. in August of the previous year, highlighting its potential in the global market.- Flcube.com
